Novo Nordisk on Monday announced a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the ...

Novo Nordisk will explore how GLP-1 drugs could help patients struggling with addiction, its head of development Martin Holst Lange told an online press conference on Thursday.

“Novo Nordisk is dedicated to providing improved treatment options for people living with obesity, type 2 diabetes, and other cardiometabolic diseases. The addition of a candidate targeting glucagon, ...

Guangdong, China and Bagsværd, Denmark, 24 March 2025 –The United Laboratories International Holdings Limited (TUL) and Novo Nordisk A/S ... of the receptors for GLP-1, GIP, and glucagon ...

The issuer is solely responsible for the content of this announcement.

Novo Nordisk announced Monday a $2 billion deal with a Chinese company making a drug in the same GLP-1 space where the Danish company is currently the leading player. Novo Nordisk said it's paying ...

Novo Nordisk (NVO) is now offering its GLP-1 weight-loss drug Wegovy direct to consumers at over half its price, amounting to $499 per month. Yahoo Finance senior health reporter Anjalee Khemlani ...

To make matters worse, on March 10, 2025, Novo Nordisk reported its CagriSema Phase 3 REDEFINE 2 CagriSema late-stage study revealed just 13.7% weight loss versus 3.1% placebo in overweight type 2 ...

Novo Nordisk (NVO) plans to run studies on how its GLP-1 class of weight loss/diabetes drug can help people deal with addiction, Martin Holst Lange, the Danish pharma’s head of development ...